Evidence map›Paper›PMID 40520577›Full record

ArticleMolecular therapy. Oncology2025

Preclinical development and clinical safety assessment of a synthetic peptide conjugate enabling endogenous antibody binding to promote innate receptor engagement.

Erika A K Fletcher, Robert A Cordfunke, Aikaterini Nasi, Gunilla Törnqvist, Rob R P M Valentijn, Anna Bergqvist, Marita Westhrin, Wenche Rasch, Frida Lindqvist, Inken Dillmann and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Erika A K FletcherDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.
Robert A CordfunkeDepartment of Immunology, Leiden University Medical Center, 2300 Leiden, the Netherlands.
Aikaterini NasiDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.
Gunilla TörnqvistDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.
Rob R P M ValentijnDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2300 Leiden, the Netherlands.
Anna BergqvistUltimovacs ASA, 0379 Oslo, Norway.
Marita WesthrinUltimovacs ASA, 0379 Oslo, Norway.
Wenche RaschUltimovacs ASA, 0379 Oslo, Norway.
Frida LindqvistDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.
Inken DillmannDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.
Martin LordDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.
Neanke BouwmanDepartment of Clinical Pharmacy and Toxicology, Leiden University Medical Center, 2300 Leiden, the Netherlands.
Jacques J NeefjesDepartment of Cell and Chemical Biology, Leiden University Medical Center, 2333 Leiden, the Netherlands.
Kees L M C FrankenDepartment of Infectious Diseases, Leiden University Medical Center, 2300 Leiden, the Netherlands.
Stephanie McArdleNottingham Trent University, Nottingham NG1 4FQ, UK.
Murrium AhmadNottingham Trent University, Nottingham NG1 4FQ, UK.
Silvia JohanssonDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85 Uppsala, Sweden.
Ferry OssendorpDepartment of Immunology, Leiden University Medical Center, 2300 Leiden, the Netherlands.
Michael HaggmanUppsala Akademiska sjukhuset, 751 85 Uppsala, Sweden.
Maria LampinenDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.
Gustav UllenhagDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, 751 85 Uppsala, Sweden.
Sam LadjevardiUppsala Akademiska sjukhuset, 751 85 Uppsala, Sweden.
Justyna Leja-JarbladImmuneed AB, 753 41 Uppsala, Sweden.
Wolfgang LillebyOslo University Hospital, 0450 Oslo, Norway.
Jan Wouter DrijfhoutDepartment of Immunology, Leiden University Medical Center, 2300 Leiden, the Netherlands.
Sara M MangsboDepartment of Pharmacy, Science for Life Laboratory, Uppsala University, 751 24 Uppsala, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peptide-based vaccines can be used to deliver tumor-specific antigens to dendritic cells (DCs), leading to tumor-directed T cell responses. We previously developed a peptide-peptide conjugate technology enabling

Indexed as

cancer vaccinedendritic cellsimmunotherapyMT: Regular Issuepeptide-conjugate vaccineprostate cancertetanus toxoid

Identifiers

PMID40520577
PMCPMC12166800

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.